It should be injected into the lesion in a well-equipped hospital setting by a healthcare professional.
The lesion and surrounding areas should be cleaned with an alcohol swab after which a local anesthetic is injected around the periphery of the lesion. Then, T-VEC is injected into the lesions evenly and completely until the full dose is uniformly dispersed.
After injection, pressure should be applied to the injection site(s) with a sterile gauze for at least 30 seconds. The site should be kept clean and dry.
Patients are advised to cover the injection site for at least a week.
1ml single-use vial contains: 106 plaque-forming units (PFU) per ml as 1st dose up to 4ml can be given for all the lesions and 108 PFU per ml for the subsequent
• If there is an allergy or hypersensitivity to Talimogene.
• Pregnant and breastfeeding women.
• Patients with low immunity, leukemia (blood cancer), AIDS or any HIV related illnesses, and those on immunosuppressive therapy. As it is an inactivated herpes virus it can cause life-threatening herpes infection in patients who are having low immunity.
The lesion and surrounding areas should be cleaned with an alcohol swab after which a local anesthetic is injected around the periphery of the lesion. Then, T-VEC is injected into the lesions evenly and completely until the full dose is uniformly dispersed.
After injection, pressure should be applied to the injection site(s) with a sterile gauze for at least 30 seconds. The site should be kept clean and dry.
Patients are advised to cover the injection site for at least a week.
Dosage & When it is to be taken
T-VEC should be given by injection into skin or into nodal lesions of melanoma that are visible, palpable (easy to touch) or identifiable using ultrasound guidance.1ml single-use vial contains: 106 plaque-forming units (PFU) per ml as 1st dose up to 4ml can be given for all the lesions and 108 PFU per ml for the subsequent
When it is not to be taken (Contraindications)
T-VEC should not be used in patients-• If there is an allergy or hypersensitivity to Talimogene.
• Pregnant and breastfeeding women.
• Patients with low immunity, leukemia (blood cancer), AIDS or any HIV related illnesses, and those on immunosuppressive therapy. As it is an inactivated herpes virus it can cause life-threatening herpes infection in patients who are having low immunity.
